Tag Archive for: drug discovery

Outrun Therapeutics expands leadership team with appointment of Matthew Fyfe as Chief Scientific Officer

/in

Brings extensive small molecule drug discovery, development, and clinical experience across multiple therapeutic areas Will drive application of Outrun’s novel, proprietary X-E3L platform for protein stabiliser discovery to develop a pipeline of high-quality drug candidates targeting E3 ligases Continues strong momentum following 2024 emergence from stealth with $10M seed financing Dundee, Scotland – 13 January […]

Read more

General Inception acquires Enable Medicine and announces strategic partnership to accelerate drug discovery with AI-led generative biological search

/in

Enable Medicine is at the forefront of using generative AI models to search vast cellular atlases of disease to discover new therapeutic insights Partnership will greatly boost the two companies’ drug discovery and development capabilities It comes after their first collaboration that led to Ennovate Pharma SAS, working on highly promising targets in autoimmune and […]

Read more

Curve Therapeutics continues to enhance leadership team with appointment of Rab Prinjha as Chief R&D Officer

/in

Deep expertise in leading drug discovery programs across oncology, neuroscience and epigenetics Will drive advancement of Curve’s rich pipeline of first-in-class therapeutic assets Builds on recent leadership team appointments, including Andre Hoekema as Chair of the Board Southampton, UK, 9 October 2024 – Curve Therapeutics (“Curve” or the “Company”), a private biotechnology company pioneering a […]

Read more

Curve Therapeutics further strengthens leadership team with the appointment of Andre Hoekema as new Chair of Board

/in

Dr Hoekema brings over four decades of successful biotech and life science leadership Dr Cora Griffin appointed to head up business development, follows recent appointment of Simon Jones as CFO/COO New hires to accelerate ambition to turbocharge the discovery platform, develop innovative therapeutic pipeline and expand pharma relationships Southampton, UK, 2 October 2024 – Curve […]

Read more

Kling Biotherapeutics to Present Discoveries on its Primary B-Cell Screening Platform at the ESMO Targeted Anticancer Therapies Congress

/in

Kling reports on advancing pipeline of therapeutic antibodies targeting novel antigens discovered with its best-in-class B-cell screening platform, Kling-Select Progress on in vitro and in vivo validation of two highly specific tumor antigens is reported: CD43s, a sialylated-glyco epitope, and U5snRNP200, an ectopically expressed antigen highly specific for AML blast. Lead program KBA1412 is advancing […]

Read more